Surgical Science Q3 2022: Dissecting the company’s Q3 numbers - Redeye

Redeye updates its estimates following Surgical Science’s Q3 2022 report, which we judge featured solid sales growth and profitability. We believe that weak cash flow during the quarter could be a concern if it persists long-term.

Länk till analysen i sin helhet: https://www.redeye.se/research/862760/surgical-science-q3-2022-dissecting-the-companys-q3-numbers?utm_source=finwire&utm_medium=RSS